,107 The PDO cohort was limited in size but reflective of real-world diversity, capturing the interplay between tumor differentiation, CDX2 expression, and KRASmut status; larger cohorts and randomized clinical trials with RNA-seq endpoints is warranted. This evidence concerns the gene CDX2 and neoplasm.